In just the past few days, Paragon Health Institute was featured on the opinion pages of The Wall Street Journal three times.
Yesterday, the Journal published Dr. Joel Zinberg’s op-ed on the Biden administration’s “haphazard micromanagement of monoclonal antibodies to treat Covid-19” and how its on-again, off-again approach “has created supply shortages, spread confusion, probably harmed patients, and undermined future treatment.” Dr. Zinberg directs Paragon’s initiative on Public Health and American Well-being.
Zinberg concluded his piece with important recommendations to Washington policymakers: “The FDA and other agencies should provide accurate, up-to-date information and ensure an adequate supply and variety of treatments. Washington bureaucrats’ micromanagement of COVID-19 treatments that are safe and effective in varying circumstances has to stop.” You can read the entire piece here.
As I mentioned in Monday’s newsletter, Paragon Public Advisor Al Hubbard and I wrote an op-ed on nonprofit hospitals’ contribution to rising health care spending. You can read our op-ed here.
The Journal also published a letter I penned in response to an editorial on improper Medicaid payments, which have become especially problematic with Obamacare expansion and is a topic I’ve written about over the past several years.
When we founded Paragon a few short months ago, our goal was to become the nation’s premier health care policy research institute that aims to improve health care and lower prices by empowering patients, expanding competition in the market, and increasing innovation. Part of this involves educating policymakers and the public about current problems with our health sector and government programs.
We’re grateful for the opportunity to frequently appear in the nation’s most prestigious paper.
Best,
Brian Blase
President
Paragon Health Institute
Brian Blase, Ph.D., is the President of Paragon Health Institute. Brian was Special Assistant to the President for Economic Policy at the White House’s National Economic Council (NEC) from 2017-2019, where he coordinated the development and execution of numerous health policies and advised the President, NEC director, and senior officials. After leaving the White House, Brian founded Blase Policy Strategies and serves as its CEO.
